NCT02405065View on ClinicalTrials.gov

Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

January 12, 2015

Primary Completion Date

January 18, 2017

Study Completion Date

May 16, 2018

Conditions
Neoplasms
Interventions
DRUG

HM95573

BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops

Trial Locations (1)

05545

Hanmi Clinical, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY